Bausch Health Cos., Inc. (BHC.TO)
9.23
+0.41
(+4.65%)
CAD |
TSX |
Aug 24, 16:00
Bausch Health Cos. Enterprise Value : 31.70B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 31.70B |
| August 21, 2026 | 31.55B |
| August 20, 2026 | 31.77B |
| August 19, 2026 | 31.79B |
| August 18, 2026 | 31.86B |
| August 17, 2026 | 31.65B |
| August 14, 2026 | 31.62B |
| August 13, 2026 | 31.55B |
| August 12, 2026 | 31.47B |
| August 11, 2026 | 31.49B |
| August 10, 2026 | 31.55B |
| August 07, 2026 | 31.50B |
| August 06, 2026 | 31.34B |
| August 05, 2026 | 31.54B |
| August 04, 2026 | 31.64B |
| July 31, 2026 | 31.86B |
| July 30, 2026 | 31.40B |
| July 29, 2026 | 30.70B |
| July 28, 2026 | 30.64B |
| July 27, 2026 | 30.62B |
| July 24, 2026 | 30.58B |
| July 23, 2026 | 30.60B |
| July 22, 2026 | 30.66B |
| July 21, 2026 | 30.63B |
| July 20, 2026 | 30.72B |
| Date | Value |
|---|---|
| July 17, 2026 | 30.78B |
| July 16, 2026 | 30.84B |
| July 15, 2026 | 30.81B |
| July 14, 2026 | 30.75B |
| July 13, 2026 | 30.82B |
| July 10, 2026 | 30.78B |
| July 09, 2026 | 30.82B |
| July 08, 2026 | 30.85B |
| July 07, 2026 | 30.86B |
| July 06, 2026 | 30.80B |
| July 03, 2026 | 30.85B |
| July 02, 2026 | 30.85B |
| June 30, 2026 | 30.86B |
| June 29, 2026 | 31.13B |
| June 26, 2026 | 31.08B |
| June 25, 2026 | 31.35B |
| June 24, 2026 | 31.20B |
| June 23, 2026 | 31.10B |
| June 22, 2026 | 31.03B |
| June 19, 2026 | 31.01B |
| June 18, 2026 | 31.07B |
| June 17, 2026 | 31.06B |
| June 16, 2026 | 31.14B |
| June 15, 2026 | 31.16B |
| June 12, 2026 | 31.20B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| HLS Therapeutics, Inc. | 155.36M |
| Cipher Pharmaceuticals, Inc. | 345.95M |
| BioSyent, Inc. | 169.97M |
| Revive Therapeutics Ltd. | 10.94M |
| Knight Therapeutics, Inc. | 873.52M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 359.94M |
| Revenue (Quarterly) | 3.948B |
| Total Expenses (Quarterly) | 3.591B |
| EPS Diluted (Quarterly) | 0.9446 |
| Gross Profit Margin (Quarterly) | 65.04% |
| Profit Margin (Quarterly) | 9.12% |
| Earnings Yield | -43.95% |
| Operating Earnings Yield | 109.4% |
| Normalized Earnings Yield | 8.277 |